Blog

Peptides for Body Recomposition

Stephen M. Walker II • April 2, 2026

This content is for informational purposes only and is not a substitute for professional advice.

You have heard the word "peptides" used to describe everything from Ozempic to a collagen powder to a black-market vial from a research-chemical lab. Nobody in the gym, on your favorite podcast, or in any Reddit thread seems to be using the same definition. That is the core problem. The word covers four completely different categories of compounds with different evidence bases, different regulatory realities, different athlete-eligibility consequences, and different risk profiles.

When a single article or a single clinic homepage flattens all four into one list of "best peptides for recomposition," the reader cannot make a good decision because the decision framework has already been destroyed. This article is the map. It splits the peptide landscape into its real categories, walks through the evidence and the gaps in each one, and gives you a framework for figuring out which lane you are actually in before you talk to a physician, a coach, or your own training log.

Every trial claim in this article is cited to its primary source. Every compound is classified by FDA approval status, WADA prohibition status, and the quality of its human evidence base. If you already know which category you are in, use the section headings to jump directly there.

The Four-Category Problem Nobody Explains

Why "peptides" is a broken word in fitness culture

In biochemistry, a peptide is a chain of amino acids shorter than what most scientists would call a protein. That definition covers thousands of molecules. Insulin is a peptide. Oxytocin is a peptide. The collagen fragments in a supplement powder are peptides. The semaglutide molecule in a Wegovy pen is a peptide. The BPC-157 compound sold from a grey-market lab with "not for human consumption" on the label is also a peptide. Saying you are interested in "peptides for body recomposition" is roughly as specific as saying you are interested in "chemicals for performance." The category is too wide to carry a useful recommendation.

The problem gets worse because fitness culture, anti-aging clinic marketing, Reddit threads, and podcast conversations all use the word differently without acknowledging the difference. In a gym locker room, "peptides" usually means grey-market injectables like BPC-157 or growth hormone secretagogues. On a podcast, it might mean Ozempic. On a supplement shelf, it means collagen. In a telehealth clinic ad, it might mean all of them at once, sold in the same tone with the same urgency.

When you collapse four distinct categories into one word, you create real risk. A man who hears that "peptides" helped someone lose thirty pounds might assume that the BPC-157 vial he found online works the same way as the semaglutide prescription his friend used. A competitive CrossFit athlete who hears that "peptides are fine" from a training partner might not realize that the compound in question is prohibited under WADA rules. A lifter who counts his collagen shake toward his daily protein target might wonder why his strength is sliding even though the tracker says he hit 180 grams. These are not hypothetical errors. They happen because the language encourages them.

This article enforces a four-category taxonomy from start to finish. Every compound discussed here belongs to one of four lanes, and those lanes do not blend.

The four sub-categories

Each of these categories requires a fundamentally different conversation. Mixing them together is the source of most bad peptide decisions.

GLP-1 receptor agonists

The conversation is about prescription access, insurance coverage, titration protocols, body-composition monitoring, and the specific training and protein strategies that prevent lean-mass loss during a medication-assisted cut. This is a structured medical conversation with a prescribing physician.

Growth hormone secretagogues

The conversation is different. Tesamorelin has a real FDA label, but the approved indication is narrow. Off-label use requires a specialist who understands the specific clinical context, the IGF-1 and glucose-tolerance risks, and the difference between what the data supports and what clinic marketing implies. For compounds like CJC-1295 and ipamorelin, there is no legitimate prescribing pathway because these compounds are not approved.

Research peptides

There is no physician conversation to have in any standard clinical sense. These compounds are not approved for human use. Buying them from a website that says "research use only" is not the same thing as participating in a clinical trial. The correct conversation is with a sports medicine physician who can help you address the underlying problem, usually load management, recovery optimization, or rehab progression, through approaches that have actual evidence behind them.

Collagen peptides

The conversation is about supplementation, not therapy. Collagen does not require a prescription. It also does not count as a complete protein source for muscle-retention purposes, and getting that wrong can quietly undermine a recomposition phase even when everything else looks right on paper.

GLP-1 Therapies and Recomposition: The Approved Foundation

What GLP-1 receptor agonists actually do

GLP-1 stands for glucagon-like peptide-1, a hormone your gut produces after meals. It signals satiety, slows gastric emptying, and helps regulate blood glucose by stimulating insulin release in a glucose-dependent manner. A GLP-1 receptor agonist is a drug that activates the same receptor with a longer duration of action than the native hormone, creating sustained appetite suppression and improved glycemic control.

For body recomposition, the mechanism that matters most is the appetite effect. GLP-1 receptor agonists reduce hunger and food noise in a way that makes it dramatically easier to sustain a calorie deficit. That is both the benefit and the risk. When appetite drops and food volume shrinks, total protein intake tends to drop with it. If protein falls below the floor needed to support muscle protein synthesis and if resistance training quality degrades because of under-fueling, the medication creates a situation where fat loss and lean-mass loss happen together. That is weight loss without recomposition, and the difference shows up in training performance before it shows up in the mirror.

The recomposition window on a GLP-1 medication exists when three conditions hold at the same time:

1. Sustained calorie deficit. The drug is doing its job on the appetite side, making a deficit feel manageable rather than punishing.
2. Protein intake at or above the lean-mass floor. This means 1.6 g/kg or higher of complete protein per day for trained lifters, spread across three to four feedings.
3. Resistance training with enough intensity and volume. The body needs a mechanical reason to preserve muscle tissue. Walking alone does not provide that signal.

When all three conditions are met, GLP-1 therapy becomes one of the most evidence-supported tools available for changing body composition in adults with overweight or obesity. When any one of the three conditions breaks, the tool starts working against the goal.

This is why the GLP-1 diet guide exists as a foundation layer, and why how to preserve muscle on GLP-1 medications is the most important companion read for any lifter considering these drugs.

Semaglutide

Semaglutide is the most extensively studied GLP-1 receptor agonist for weight management. The STEP clinical trial program provides the primary evidence base for its use in obesity.

STEP 1

STEP 1 enrolled adults with overweight or obesity without diabetes. At 68 weeks, the semaglutide group achieved a mean weight loss of 14.9 percent compared to 2.4 percent in the placebo group. The body-composition sub-analysis showed that semaglutide reduced both fat mass and lean mass in absolute terms. Fat mass decreased by approximately 8.4 kg and lean mass decreased by approximately 5.3 kg.¹

That lean-mass number is the one that should concern any lifter. It is also the number that context can change, because the trial population was not resistance-trained and the lifestyle intervention did not include a structured progressive-overload program.

STEP 2

STEP 2 examined semaglutide in adults with type 2 diabetes and overweight or obesity. Weight loss was more modest than STEP 1, which is typical in diabetes populations because insulin resistance and glycemic control create a different metabolic environment. The mean weight loss with semaglutide 2.4 mg was approximately 9.6 percent at 68 weeks versus 3.4 percent with placebo.²

For lifters with type 2 diabetes who are considering semaglutide, the lower magnitude of weight loss compared to STEP 1 is worth knowing because it sets more realistic expectations about timeline and the degree of appetite suppression they are likely to experience.

STEP 3

STEP 3 combined semaglutide with intensive behavioral therapy, including a low-calorie diet phase followed by ongoing counseling and physical activity support. The result was a mean weight loss of approximately 16.0 percent at 68 weeks, which exceeded STEP 1.³

This illustrates a principle that matters for the recomposition audience: structured behavioral support amplifies the pharmacological effect. The training and nutrition protocol you build around the drug is a multiplier of the outcome. Men who treat the prescription as a standalone solution and change nothing about their training, protein strategy, or meal architecture get less out of it than men who use the appetite window to install better systems.

STEP 4

STEP 4 used a randomized withdrawal design that reveals the other side of the equation. Participants who achieved weight loss on semaglutide were randomized to continue the drug or switch to placebo. Those who continued maintained their weight loss. Those switched to placebo regained approximately two-thirds of the lost weight over the subsequent 48 weeks.⁴

That regain pattern is consistent with what happens after any intervention that reduces body weight without permanently changing the biological drivers of weight regulation. For a lifter, the STEP 4 result means that the off-ramp matters as much as the on-ramp. If you do not build maintenance habits, protein systems, and training consistency while the drug is suppressing appetite, you will not have them when the drug stops. That planning process is the subject of how to stop GLP-1s without rapid fat regain.

SELECT

SELECT added cardiovascular outcome data. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease, without diabetes.⁵ That trial moved semaglutide beyond a weight-loss-only framing and into a cardiovascular risk reduction tool, which changes the clinical calculus for physicians deciding whether to prescribe.

The key insight for lifters from the semaglutide data is that the drug does not inherently cause disproportionate muscle loss. It causes weight loss, and a meaningful fraction of that weight loss comes from lean tissue unless you actively protect against it. The protection protocol is straightforward: adequate protein, resistance training, and a rate of loss that your training performance can survive. That protocol is detailed in protein targets and training strategy on semaglutide or retatrutide.

The dose matters. Semaglutide 2.4 mg per week is the approved maintenance dose for weight management, and it produces substantially more appetite suppression than the lower titration doses used during the first several months. Many of the protein and training problems show up during or after the titration to full dose, when appetite suppression reaches its peak and men who were eating adequately at 0.5 or 1.0 mg suddenly find that they cannot finish a normal meal. Planning the protein strategy before reaching the full dose, rather than reacting to under-fueling after it has already started, is the practical difference between a productive cut and a messy one.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. GIP stands for glucose-dependent insulinotropic polypeptide, and the co-agonism at both receptors appears to produce greater weight loss than GLP-1 receptor agonism alone, though the clinical significance of the GIP component for body composition specifically is still being studied.

SURMOUNT-1

SURMOUNT-1 enrolled adults with obesity or overweight plus at least one weight-related comorbidity, excluding diabetes. At 72 weeks, tirzepatide produced mean weight reductions of 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, versus 3.1 percent with placebo.⁶ Those numbers represent a clear step up from semaglutide's STEP 1 results, though cross-trial comparisons have well-known limitations.

SURMOUNT-2

SURMOUNT-2 examined tirzepatide in adults with type 2 diabetes and obesity or overweight. Weight loss was substantial even in the diabetes population, with the 15 mg arm producing a mean reduction of 14.7 percent at 72 weeks.⁷ That is notable because weight loss in people with type 2 diabetes is generally harder to achieve and smaller in magnitude with most interventions. For a lifter with type 2 diabetes who has struggled to lose fat on previous approaches, tirzepatide represents a real option, but the same lean-mass protection rules apply, and arguably apply more urgently because metabolic disease already increases the importance of preserving muscle tissue as a glucose-disposal organ.

The GI side-effect profile on tirzepatide is worth understanding for training purposes. Nausea, diarrhea, and reduced appetite are the most commonly reported adverse events in the SURMOUNT program, and they tend to be most pronounced during dose escalation. For lifters, the titration phase is the highest-risk period for under-fueling. Planning protein-dense, small-volume meals before the dose increase, rather than reacting to appetite loss after it arrives, is the practical difference between maintaining training quality and watching it erode over several weeks.

SURMOUNT-5

SURMOUNT-5 was a head-to-head trial comparing tirzepatide to semaglutide. Tirzepatide produced greater weight loss, but the trial's primary design was not powered to answer the body-composition question with the granularity that lifters want.⁸ What SURMOUNT-5 does tell us is that tirzepatide at the highest dose produces more total weight loss than semaglutide at 2.4 mg, which means the absolute amount of lean mass at risk is potentially larger, which means the protein and training guardrails matter even more.

The practical implication is the same as with semaglutide, only more so. Greater appetite suppression means greater risk of under-eating protein. Greater total weight loss means greater absolute lean-mass exposure. The drug is more powerful, but the protection protocol does not change. It just becomes less optional.

Retatrutide

Retatrutide is a triple agonist that acts on GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor agonism is what makes it mechanistically distinct from tirzepatide, and the early data suggests that the triple mechanism may produce even greater weight loss.

Phase 2 obesity data

The phase 2 trial, published in the New England Journal of Medicine, showed a least-squares mean weight reduction of 24.2 percent in the 12 mg retatrutide arm at 48 weeks, compared to 2.1 percent with placebo.⁹ That is the largest weight-loss number from any incretin-class drug in a controlled trial to date. It is also a phase 2 result, which means the sample size is smaller, the follow-up is shorter, and the safety profile is less fully characterized than what we have for semaglutide or tirzepatide.

Regulatory status

Retatrutide is not FDA-approved. The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. That means the vials of retatrutide available through grey-market sources and some compounding pharmacies exist in a regulatory space that the agency considers unlawful.

When someone tells you they are "on retatrutide," the compound they are injecting may or may not be what the label says it is, and the oversight that normally protects patients in approved-drug pathways is absent.

Body-composition data

The substudy in adults with type 2 diabetes showed fat-mass reductions of 15.2 percent at pooled 4 mg, 26.1 percent at pooled 8 mg, and 23.2 percent at 12 mg by week 36. The authors noted that the proportion of lean-mass loss relative to total weight loss was similar to other obesity treatments.¹⁰ That observation means retatrutide does not appear to be selectively sparing muscle. The lean-mass fraction of weight loss looks roughly the same as with other drugs in this class, which means the absolute amount of lean mass lost is larger simply because total weight loss is larger.

Phase 3 timeline

Eli Lilly has reported positive topline Phase 3 results in type 2 diabetes and osteoarthritis-linked obesity programs. The broader obesity Phase 3 program is ongoing, and FDA submission timing has not been confirmed as of April 2026.

Retatrutide belongs in the emerging tier of the evidence framework. It is interesting. It may eventually become the most effective obesity medication available. But semaglutide and tirzepatide already provide strong, evidence-backed, legally prescribed options for the same goal.

The recomposition floor {#recomposition-floor}

GLP-1 therapy without resistance training is a body-composition failure mode. The data supports this clearly. Weight loss without a mechanical signal to preserve muscle leads to lean-mass loss that is proportional to the deficit and often accelerated by the drug-induced appetite suppression that makes chronic under-fueling feel comfortable rather than alarming.

Protein floor

The minimum daily protein intake below which lean-mass protection becomes unreliable. For the general GLP-1 patient population, the 2025 multi-society advisory on nutritional priorities during GLP-1 therapy recommends 1.2 to 1.6 g/kg adjusted body weight per day with strength training.¹¹ For trained lifters in a deficit, the sports-nutrition literature supports higher intakes, often in the range of 1.6 to 2.2 g/kg, and sometimes higher during aggressive cuts.¹²¹³

Rate-of-loss guardrail

For most men on semaglutide, keeping weight loss at or below 0.5 to 1.0 percent of body weight per week preserves the conditions under which muscle retention is most likely. For men on tirzepatide or retatrutide, the stronger appetite suppression often pushes loss rates above that range unless caloric intake is deliberately maintained, and the practical guardrail may need to be tighter at 0.5 to 0.8 percent per week when training quality matters.

Training signal

Resistance training at least three to four times per week with compound lifts provides the mechanical stimulus that tells the body to preserve muscle. Keep intensity high and trim volume before trimming load. If a session feels flat once, that is normal. If sessions feel flat for two consecutive weeks, assume under-fueling before changing the program.

The most common failure mode on GLP-1 therapy does not look like failure at first. The scale drops fast. Clothes fit better. People comment on the change. The problem is invisible for the first four to eight weeks because the mirror does not distinguish between fat loss and lean-mass loss at small magnitudes. By the time training performance has clearly degraded, the lifter has already lost tissue that took months or years to build. The cost of undoing that mistake is much higher than the cost of setting the floor correctly from the start.

Walking is valuable but does not replace lifting. Walking supports metabolic health, energy expenditure, and adherence. It does not create the mechanical tension needed to signal muscle preservation. The more productive response to training fatigue on a GLP-1 medication is to maintain intensity while reducing volume, improve pre-training nutrition, and audit sleep.

Here is the canonical recomposition floor protocol. Every scenario and decision framework later in this article references back to this list.

1. Set your daily protein floor at 1.6 g/kg or higher of complete protein, distributed across three to four feedings of 30 to 50 grams each.
2. Lift at least three times per week with compound movements. Prioritize squats, deadlifts, presses, rows, and pull-ups. Keep load high and reduce volume before reducing intensity.
3. Monitor your 14-day weight trend weekly. Flag any two-week stretch where loss exceeds 1.0 percent of body weight per week.
4. Track two to four anchor lifts for performance stability. Two consecutive weeks of declining performance at the same effort level means under-fueling until proven otherwise.
5. On low-appetite days, use liquid protein sources (whey shakes, Greek yogurt, casein drinks) to hit the floor without requiring large meal volumes.
6. Plan the protein strategy before reaching full dose. Reacting to under-fueling after appetite suppression peaks is harder than preventing it.

GLP-1 and athletic use

As of the 2026 WADA Prohibited List, GLP-1 receptor agonists are not classified as prohibited substances. They do not appear in any section of the list. That means a tested athlete can currently use a prescribed GLP-1 medication without triggering an anti-doping violation, provided the substance is confirmed not prohibited at the time of use. Athletes should verify current status with USADA or their relevant anti-doping authority before competition because the list is updated annually and the regulatory landscape around these drugs is evolving.

The framing that "it is just a diet drug" is incomplete for athletes. While GLP-1 receptor agonists are not performance-enhancing in the traditional sense, their use in weight-class sports, endurance events with power-to-weight considerations, or aesthetic competitions raises questions about competitive fairness that governing bodies may eventually address.

A Therapeutic Use Exemption is not required for GLP-1 medications under the current rules because they are not prohibited. If a future update to the Prohibited List changes that status, a TUE process would apply, and the clinical documentation for the prescription would become relevant. This is another reason why having a legitimate prescription through a standard medical pathway matters more than sourcing through a convenience-first telehealth service.

For athletes in weight-class sports like wrestling, judo, powerlifting, and Olympic weightlifting, the recomposition angle of GLP-1 therapy adds a layer of strategic complexity. These drugs can make it substantially easier to compete at a lower weight class with better body composition, which creates a competitive advantage that is not currently addressed by anti-doping rules. Whether governing bodies will eventually decide that this advantage is inconsistent with the spirit of sport is an open question, but athletes in these disciplines should be aware that the conversation is happening and that the permissibility they enjoy today may not extend indefinitely.

GLP-1 medications create a different set of tradeoffs for endurance competitors. The power-to-weight ratio improvement from losing fat can improve performance on running, cycling, and other body-weight-dependent efforts. At the same time, under-fueling on these drugs can impair glycogen availability, compromise training quality during high-volume blocks, and degrade recovery between sessions. Endurance athletes using GLP-1 therapy should pay particular attention to carbohydrate availability around key training sessions and should not assume that the appetite-suppression benefit is always net positive during periods of high training load.

The broader point for any competitive athlete is that "not prohibited" is not the same as "no considerations." The current WADA and USADA positions are permissive, but the clinical, ethical, and practical dimensions of using these drugs in competitive contexts deserve more thought than a simple rule check provides.

Growth Hormone Secretagogues: The Approved Tier That Gets Conflated With Everything Else

What growth hormone secretagogues are and what they are not

A growth hormone secretagogue is a compound that stimulates the pituitary gland to release growth hormone. This is fundamentally different from exogenous growth hormone injection, where the hormone itself is administered directly. Secretagogues work by triggering endogenous release, which means the body's own feedback mechanisms still influence the outcome to some degree. That distinction matters because it changes the safety profile, the magnitude of effect, and the regulatory classification.

Gym culture frequently conflates growth hormone secretagogues with research peptides, and the conflation runs in both directions. Some people treat tesamorelin, which has an FDA-approved label and real clinical trial data, as though it belongs in the same category as BPC-157, which has no approved human use. Others treat CJC-1295 and ipamorelin, which are not FDA-approved, as though they carry the same evidentiary weight as tesamorelin simply because they all affect the growth hormone axis. Neither conflation is accurate.

The critical distinction within this category is between compounds that have FDA approval for a specific indication and compounds that do not. Tesamorelin is approved. Everything else commonly marketed as a growth hormone secretagogue for body composition, including sermorelin in its current compounding-pharmacy form, CJC-1295, ipamorelin, and various GHRH/GHRP combinations, is either not approved or operating on a withdrawn approval that no longer supports current prescribing.

Tesamorelin

Tesamorelin is a growth hormone-releasing factor analog approved by the FDA under the brand name EGRIFTA. The approved indication is specific: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The EGRIFTA labeling explicitly states that tesamorelin is not indicated for weight-loss management. That one sentence from the prescribing information clears up more confusion than most of the marketing copy surrounding this drug.

Clinical trial data

The pivotal phase 3 trials enrolled HIV-infected adults with excess abdominal fat and demonstrated that tesamorelin reduced visceral adipose tissue area measured by CT scan by approximately 15 to 18 percent over 26 weeks compared to placebo. Trunk fat also decreased, and the effects were specific to the visceral compartment rather than representing generalized weight loss.¹⁴ That specificity is part of what makes the drug interesting to the recomposition audience, but it is also part of what makes the extrapolation from the approved population to a healthy lifter problematic.

Safety concerns

The FDA medical review for NDA 022505 flagged two key issues. First, tesamorelin elevated IGF-1 levels, which is expected given its GH-releasing mechanism but raises long-term questions about cancer risk and other IGF-1-mediated effects that require monitoring. Second, glucose tolerance was affected, with some patients showing worsening glycemic control.¹⁴

For a man with insulin resistance or prediabetes considering off-label tesamorelin, the glucose-tolerance signal is directly relevant and needs to be discussed with an endocrinologist.

Reversal on discontinuation

Patients who stopped tesamorelin regained visceral fat during the off-treatment period. That means tesamorelin is not a one-time intervention that permanently resets visceral fat. It is an ongoing therapy, and the decision to start it should include a plan for how long treatment will continue and what happens after it stops.

The honest framing for the recomposition audience is this: tesamorelin has real data showing it reduces visceral fat in a specific clinical population. That data does not automatically extend to a healthy 35-year-old lifter who wants to get leaner for summer. Off-label use is a physician decision, and a legitimate off-label conversation looks very different from a peptide-clinic website that lists tesamorelin alongside BPC-157 and collagen in the same "body optimization" package.

A legitimate clinical conversation about tesamorelin involves a physician who understands the HIV-lipodystrophy data, the IGF-1 monitoring requirements, the glucose-tolerance implications, the cost, and the distinction between the approved indication and the patient's actual clinical picture. It does not involve a telehealth intake form that asks three questions and then ships a vial.

If you are a man with visceral fat accumulation and you are genuinely interested in whether tesamorelin could be part of your clinical care, the pathway is a referral to an endocrinologist or an obesity medicine specialist who can evaluate whether your situation warrants off-label consideration.

Sermorelin

Sermorelin has a complicated regulatory history that most peptide content ignores. The original FDA-approved sermorelin products were Geref Diagnostic, used for evaluating pituitary function, and Geref, indicated for the treatment of idiopathic growth hormone deficiency in children. Both NDAs were subsequently withdrawn by the applicant. The products left the market, and the approved indications are no longer actively supported by a marketed product.

What exists today is sermorelin available through compounding pharmacies, often marketed by anti-aging clinics as a growth hormone support therapy for body composition, sleep quality, and recovery. The regulatory status of compounded sermorelin is materially different from the status of a currently marketed FDA-approved drug. Compounded drugs are not FDA-approved and do not undergo the same manufacturing oversight, stability testing, or post-market surveillance.

The evidence base for sermorelin as a body-recomposition tool is thin. The clinical trials that supported the original Geref approval were conducted in pediatric growth hormone deficiency, not in healthy adults seeking fat loss or muscle gain. There are older, smaller studies in adults examining GH-releasing effects, but there are no modern large randomized controlled trials demonstrating that sermorelin produces clinically meaningful body-composition improvements in the population that peptide marketing targets most aggressively: men in their 30s through 50s who lift and want to get leaner.

When clinic pages talk about sermorelin as though it sits beside Wegovy or Zepbound as a clean body-composition option, they are importing anti-aging marketing language into a much messier regulatory and evidentiary reality.

For tested athletes, sermorelin is prohibited under the WADA Prohibited List. It falls under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics), which applies at all times, both in competition and out of competition. A TUE would be required, and the clinical justification for a TUE based on body-composition goals in a healthy athlete would be difficult to establish.

CJC-1295, ipamorelin, and grey-market GHRH/GHRP compounds

CJC-1295 is a synthetic analog of growth hormone-releasing hormone with a Drug Affinity Complex modification that extends its half-life. Ipamorelin is a growth hormone-releasing peptide that acts on the ghrelin receptor. Neither compound is FDA-approved. Neither has been through the clinical trial process required for approved therapeutic use in any indication.

The human data is sparse. There are small pharmacokinetic and pharmacodynamic studies showing that these compounds can increase GH secretion in humans, but there are no large randomized controlled trials demonstrating body-composition benefits, safety in long-term use, or the risk-benefit profile that would be required for regulatory approval.

These compounds are widely available through peptide clinics and online research-chemical vendors. They are often sold in combination, sometimes as a "CJC/Ipamorelin stack," and marketed with language that implies clinical legitimacy without providing the clinical evidence to back it up.

Both compounds are prohibited under the WADA framework. Any athlete subject to anti-doping testing who uses CJC-1295 or ipamorelin risks a doping violation, regardless of whether the compound was obtained through a "medical" channel.

The blur between peptide clinics and compounding pharmacies makes this category particularly confusing. A man who walks into a clinic that offers CJC-1295 and ipamorelin may believe he is receiving medical care. In practice, he may be receiving a compound that has no approved indication, no FDA manufacturing oversight, and no clinical trial evidence for the outcome he is seeking. The questions he should ask before accepting any GH-axis intervention from any source:

• What is the FDA approval status of this compound?
• What clinical trial evidence supports its use for my specific situation?
• What monitoring will you perform?
• What are the risks?

If the clinic cannot answer those questions with specifics rather than generalities, the conversation is marketing, not clinical care.

Decision framework for GH secretagogues

Before pursuing any GH-axis compound, confirm that the recomposition floor conditions are met. If protein intake, resistance training, and sleep are not already optimized, a compound is solving an adherence problem with pharmacology, and there are better ways to fix adherence.

Red flags in direct-to-consumer peptide clinic marketing include any combination of the following. The clinic markets multiple peptide categories with the same enthusiastic tone and no differentiation by evidence quality. The intake process does not include a meaningful medical history, physical examination, or lab work. The clinic describes compounded peptides as equivalent to FDA-approved drugs. The marketing uses terms like "bio-optimization," "anti-aging protocol," or "peptide therapy" without specifying what condition is being treated. The clinic discourages you from involving your primary care physician. Any one of these patterns should prompt you to slow down and seek a second opinion from a physician who does not have a financial incentive to prescribe the compound in question.

Research Peptides: Where Evidence Ends and Risk Begins

Defining the category

Research peptides are compounds sold with "for research use only" or "not for human consumption" labeling that have no approved human therapeutic use from any global regulatory authority. The label language is not a marker of purity or scientific legitimacy. It is a legal shield that allows vendors to sell compounds intended for human use while disclaiming responsibility for human outcomes.

The FDA has addressed this pattern directly. The agency's warning on unapproved GLP-1 drugs used for weight loss extends to the broader peptide supply chain and explicitly calls out products marketed as "for research purposes" or "not for human consumption" when the actual marketing, packaging, and distribution channels make clear that human use is intended.

When a website sells BPC-157 in a vial with dosing instructions, bacteriostatic water, and insulin syringes while printing "not for human consumption" on the label, the label is contradicted by every other signal the vendor is sending.

Supply chain and quality control problems in the research peptide market are well documented. These compounds are not manufactured under FDA Current Good Manufacturing Practice requirements. There is no mandatory purity testing, no stability data, no batch-to-batch consistency assurance, and no post-market adverse event reporting. Independent analyses of research peptides purchased online have found contamination, incorrect concentrations, and degradation products.

The argument that "it is legal to buy" is not a safety argument. Many things are legal to buy that are not safe to inject. The legal status of research peptides reflects a regulatory gap, not an affirmative determination of safety.

BPC-157

BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a protein found in human gastric juice. It has generated substantial interest in fitness and injury-recovery communities because of animal studies showing accelerated healing of tendons, ligaments, muscles, and other tissues in rodent models.

Animal data

The preclinical signal is real, and it is the reason the compound attracted attention in the first place. Studies in rats have shown that BPC-157 promotes angiogenesis, accelerates tendon healing, and reduces inflammation through mechanisms that include modulation of nitric oxide pathways and growth factor expression.

Human evidence gap

There are no published large randomized controlled trials demonstrating that BPC-157 produces clinically meaningful tissue repair, recovery acceleration, or body-composition benefits in humans. The gap between what the animal studies suggest and what has been demonstrated in human trials is the central problem with BPC-157 as a practical recommendation. Mechanism studies in rodents do not establish efficacy in humans. Dose translation from animal models to human use is not straightforward. And the safety profile in humans at the doses commonly used by self-experimenters has not been characterized through the kind of systematic study that would be required for regulatory approval.

USADA position

USADA's advisory on BPC-157 is unambiguous. The compound is prohibited under the WADA Prohibited List category S0, which covers Unapproved Substances. USADA states that BPC-157 is not approved for human clinical use by any global regulatory authority and that there is not enough human study to establish a safe dose or safe use pattern. USADA further notes that websites continue to sell BPC-157 as a "research chemical" while providing human-use suggestions, and the agency treats that pattern as a warning sign.

The telephone problem

The narrative that surrounds BPC-157 in gym culture is the "Wolverine peptide" story: a compound that heals everything, has no side effects, and just needs more research before it becomes mainstream. That narrative is built on animal data, anecdotes, and the assumption that absence of evidence of harm is the same as evidence of safety.

A rodent study shows that BPC-157 accelerates Achilles tendon healing in rats. That study gets cited in a blog post, which gets summarized in a forum thread, which gets mentioned on a podcast, which reaches a man with patellar tendonitis who is twelve weeks out from a HYROX event. By the time the information reaches him, it has been stripped of every qualifier that made the original study honest. The species difference is gone. The dose-translation uncertainty is gone. The fact that no one has demonstrated this effect in a controlled human trial is gone. What remains is a clean story: this peptide heals tendons.

Animal studies are hypothesis generators, not treatment recommendations. They tell us that a mechanism is plausible and worth studying further. They do not tell us that injecting a compound purchased from an unregulated vendor will produce the same effect in a human at the dose listed on a forum post.

For the recomposition audience specifically, BPC-157 has no relevance to fat loss, muscle gain, or body-composition improvement. Its claimed benefits are entirely in the tissue-repair and recovery domain. Even granting the most optimistic interpretation of the preclinical data, BPC-157 does not belong in a recomposition protocol.

For tested athletes in any federation, the answer is simple. BPC-157 is prohibited, the supply chain is unregulated, and using it risks both a doping violation and exposure to an unknown substance profile.

TB-500

TB-500 is a synthetic version of a region of thymosin beta-4, a protein involved in cell migration, angiogenesis, and wound healing. The mechanism hypothesis is that TB-500 promotes tissue repair and reduces inflammation by upregulating actin and facilitating cell movement to injury sites.

The evidence picture is similar to BPC-157 but thinner. There are in vitro and animal studies supporting the mechanistic hypothesis, but the published human evidence for TB-500 as a recovery or body-composition tool consists primarily of case reports and anecdotes. There are no large controlled human trials.

TB-500 is prohibited under the WADA framework. Like BPC-157, it falls under the category of unapproved substances, and its use by any athlete subject to anti-doping testing constitutes a violation.

The common practice of stacking TB-500 with BPC-157 compounds the problems rather than solving them. Each compound individually carries supply-chain risk, dosing uncertainty, and a weak human evidence base. Combining them does not produce a cleaner risk-benefit picture. It produces a more uncertain one, because the interaction effects of two poorly characterized compounds in an uncontrolled manufacturing environment are unknown.

Peptide stacks and amplification risk

The concept of a "peptide stack" borrows language from bodybuilding culture, where stacking refers to combining multiple compounds to amplify effects. In the context of approved pharmaceuticals with known pharmacokinetics and drug-interaction profiles, combination therapy can be rational and evidence-based. In the context of research peptides, stacking amplifies uncertainty rather than efficacy.

When two compounds each have weak or absent human evidence profiles, combining them does not produce strong evidence. It produces compounded uncertainty. You do not know what compound A does in humans at the dose you are taking. You do not know what compound B does in humans at the dose you are taking. You cannot know what the combination does, because nobody has studied it in a controlled setting with the population you belong to.

Contamination and dosing accuracy problems multiply with stacking. If one vial has a 20 percent chance of containing a concentration that differs meaningfully from the label, two vials from the same vendor do not reduce that probability. They create two independent opportunities for error.

For men aged 25 to 55 without pathology, the specific risks of research peptide stacks include exposure to unknown contaminants, immune reactions to impurities, IGF-1 elevation from GH-axis compounds without monitoring, and the psychological cost of building a recovery strategy around compounds whose effects you cannot verify.

Honest risk-benefit table for research peptides

What to do instead

The gap that research peptides claim to fill is usually a recovery gap, an injury-recovery gap, or a body-composition-progress gap. In nearly every case, the gap has identifiable causes that respond to evidence-based interventions.

Load management

Load management is the most underused tool in the recovery toolbox for men who train hard. Progressive overload does not mean progressive recklessness. When tendon pain, joint soreness, or soft-tissue complaints accumulate, the first intervention is intelligent load modification.

Practical load management looks like this: schedule a deload every four to six weeks where volume drops by 40 to 50 percent while intensity stays moderate. Use RPE-based autoregulation to back off on days when readiness is low rather than grinding through a prescribed number. For tendon complaints specifically, increase loading no more than 10 percent per week and distinguish between structural injury (sharp, localized, getting worse) and overuse adaptation (dull, diffuse, improving with warm-up). The first needs imaging and a sports medicine evaluation. The second needs patience and load management.

Sleep quality and duration

Sleep quality and duration are the single largest modifiable factor in recovery for most men who train. Chronic sleep restriction impairs muscle protein synthesis, increases cortisol, reduces testosterone, and degrades training quality. The practical targets are straightforward. Aim for seven to nine hours of sleep per night. Keep your room cool (65 to 68 degrees Fahrenheit is the most commonly recommended range). Limit bright light exposure in the two hours before bed. Maintain a consistent wake time, even on weekends, because circadian consistency improves sleep architecture more reliably than any supplement.

Sleep is also when the majority of growth hormone release occurs in healthy adults. Men who are considering GH-axis peptides while sleeping six hours per night are trying to pharmacologically replace a signal that their own pituitary would produce if they went to bed on time. Fixing sleep will do more for recovery than any peptide stack, and it costs nothing.

Protein sufficiency

Protein sufficiency protects both muscle and connective tissue during a deficit. If your protein intake is below 1.6 g/kg and you are in a caloric deficit, your tissues are under-resourced for repair. Fixing that before adding a compound is the right sequence.

Collagen peptides plus Vitamin C

Collagen peptides plus Vitamin C, taken before training, represent the closest thing to a research-peptide alternative with an actual evidence signal for connective-tissue support. The protocol, based on the work of Keith Baar and colleagues, involves 15 grams of hydrolyzed collagen or gelatin plus 50 mg of Vitamin C consumed 30 to 60 minutes before a loading session targeted at the affected tissue.¹⁵ The evidence base is small and the clinical outcomes are still being established, but the risk profile is categorically different from injecting an unregulated research compound.

Progressive overload

Progressive overload, applied intelligently, is the primary stimulus for tissue adaptation. Tendons, ligaments, and muscles all respond to mechanical loading by getting stronger. The response is slow, especially for tendons, which is why patience with loading progression matters more than acceleration through pharmacology.

The evidence-based rehabilitation pathway

The evidence-based rehabilitation pathway for a genuine injury follows a sequence that research peptides skip entirely:

1. Symptom assessment. Characterize the pain: location, onset pattern, aggravating movements, response to warm-up.
2. Imaging if indicated. A sports medicine physician can determine whether ultrasound or MRI is warranted based on the clinical picture.
3. Load-modified training. Maintain fitness in areas that do not stress the injured tissue. Remove the provocative stimulus while preserving everything else.
4. Targeted physical therapy. Progressive loading specific to the injured structure, guided by a physiotherapist who understands athletic populations.
5. Collagen plus Vitamin C protocol. 15 grams of hydrolyzed collagen plus 50 mg Vitamin C, 30 to 60 minutes before targeted loading of the affected tissue.
6. Reassessment at four to six weeks. Evaluate progress, adjust the rehabilitation plan, and determine whether additional interventions (PRP, further imaging, surgical referral) are warranted.

If you are a man who has been considering research peptides for injury recovery, the most productive first step is to book an appointment with a sports medicine physician and describe the problem honestly. Bring your training log. Bring your injury history. Ask what the diagnosis is, what the evidence-based treatment options are, and what the expected recovery timeline looks like.

Collagen Peptides: The Supplement That Deserves Its Own Lane

Why collagen peptides are in this article

Collagen peptides show up in this article because of semantic confusion. When someone searches for "peptides for body recomposition," the results often include collagen supplements alongside semaglutide and BPC-157 as though they are all part of the same conversation. They are not. Collagen peptides are a supplement. They are not a therapeutic drug, not a growth hormone modulator, and not a research compound. They belong in a completely separate decision lane, and confusing them with any of the other three categories leads to bad tracking, bad expectations, and bad protein math.

The tracking error

The most common practical mistake involving collagen is counting it as a complete protein source. Collagen is not a complete protein. It is rich in glycine, proline, and hydroxyproline but deficient in the essential amino acids, particularly leucine, that drive muscle protein synthesis. A man who logs 20 grams of collagen as 20 grams of protein in his food tracker and then uses that number to calculate whether he hit his leucine-driven protein floor is fooling his own log.

If your daily protein target is 160 grams and you are counting 20 grams from a collagen supplement, your effective protein intake for muscle-retention purposes is closer to 140 grams of complete protein. On a day when appetite is low because of GLP-1 medication, that 20-gram gap can be the difference between hitting the leucine threshold at your meals and missing it.

The guidance for logging collagen in Fuel is to track it as a supplement, not as a primary protein source. Log it for transparency and total-calorie accuracy, but do not count it toward your leucine-driven protein floor. Build your three to four protein feedings per day around complete protein sources like whey, casein, eggs, dairy, meat, fish, soy, or legume combinations. Then add collagen on top if you are using it for connective-tissue support.

What tendon and joint evidence actually shows

The Baar protocol

The most cited research on collagen peptides and connective tissue comes from the work of Keith Baar and Greg Shaw at the Australian Institute of Sport. Their protocol involves consuming gelatin or hydrolyzed collagen enriched with Vitamin C before a targeted loading session. The proposed mechanism is that collagen-derived amino acids, particularly glycine and proline, are taken up by fibroblasts and used to synthesize new collagen in tendons and ligaments, and that the Vitamin C serves as a cofactor for the hydroxylation step in collagen synthesis.¹⁵

The Shaw and Baar studies showed that gelatin plus Vitamin C supplementation increased collagen synthesis markers and improved the mechanical properties of engineered ligaments in vitro. Subsequent small human studies have shown increases in collagen synthesis biomarkers after supplementation, and some clinical trials have reported modest improvements in joint pain scores or functional outcomes in populations with osteoarthritis or exercise-related joint discomfort.

The honest summary of this evidence is: promising signal, not established clinical practice. The studies are generally small, the clinical outcomes are modest, and the translation from collagen synthesis biomarkers to meaningful injury prevention or tissue repair in trained athletes is still being established. Collagen supplementation for connective-tissue support falls into the plausible category. The risk is low, the cost is low, the mechanism is reasonable, and there are small studies showing positive signals. That makes it a reasonable thing to try if you are managing tendon or joint stress during heavy training.

For a man trying to support his tendons and joints during a hard training block, collagen plus Vitamin C before targeted loading is a reasonable, low-downside addition to a broader recovery strategy. It should not be the cornerstone of that strategy, and it does not replace load management, sleep, overall protein adequacy, or sports medicine evaluation when genuine tissue problems arise.

Sourcing, dose, and timing

Sourcing

Hydrolyzed collagen and gelatin are the two main supplemental forms. Hydrolyzed collagen dissolves easily in cold or warm liquids and is the most practical form for daily use. Gelatin requires warm liquid to dissolve and sets when cooled, which makes it less convenient for shakes but useful for making gummy-style supplements or adding to hot foods.

Raw collagen, as found in bone broth or slow-cooked connective tissue, provides collagen-derived amino acids but in less standardized amounts. For the purposes of a targeted connective-tissue protocol, hydrolyzed collagen or gelatin with a known gram amount is more practical than estimating collagen intake from whole foods.

Dose and timing

The evidence-based dose range for the Baar protocol is approximately 15 grams of hydrolyzed collagen or gelatin combined with at least 50 mg of Vitamin C, consumed 30 to 60 minutes before a targeted loading session for the connective tissue in question. The loading session can be as simple as an isometric hold or a light eccentric exercise for the affected tendon, performed in the window when collagen-derived amino acids are circulating.

Supplement labels often recommend lower doses, such as 5 to 10 grams per day, and make broad claims about skin, hair, and joint health. The research that supports connective-tissue benefit uses higher doses in a more specific protocol. If you are using collagen for tendon or joint support, dose and timing according to the research protocol rather than the marketing dose.

Emerging Compounds and the Pipeline

The GLP-1 landscape is changing faster than any other area of obesity pharmacotherapy. Several compounds in late-stage development will enter the recomposition conversation over the next one to three years. Understanding what is coming helps you evaluate marketing claims, recognize when a clinic is selling you access to an unapproved compound, and plan your own timeline.

The recomposition principles from this article apply to every compound in this section. Greater weight loss means greater absolute lean-mass exposure. The protein floor, resistance training signal, and rate-of-loss monitoring do not change because the drug changed. They become more important as the drugs become more powerful.

Survodutide

Survodutide is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim. The glucagon receptor agonism distinguishes it from tirzepatide (which acts on GIP and GLP-1) and makes the metabolic mechanism different. Glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation, which may contribute to fat loss through a pathway that GLP-1-only drugs do not access.

Phase 2 data

In the phase 2 obesity trial, survodutide at the highest tested dose produced a mean weight loss of approximately 18.7 percent at 46 weeks compared to placebo.¹⁶ The NAFLD/NASH data has been particularly notable, with survodutide showing meaningful reductions in liver fat content, which is relevant for men with metabolic syndrome who carry visceral and hepatic fat alongside subcutaneous fat.

Survodutide is currently in Phase 3 development. It is not FDA-approved and is not available through any legitimate prescribing pathway.

Orforglipron

Orforglipron is an oral nonpeptide GLP-1 receptor agonist developed by Eli Lilly. The significance is in the delivery method. Every currently approved GLP-1 receptor agonist for obesity (semaglutide, tirzepatide) is administered by injection. An effective oral GLP-1 with a small-molecule structure could change the access, cost, and adherence landscape for obesity treatment.

Phase 2 data

The phase 2 trial published in the New England Journal of Medicine showed a mean weight loss of up to 14.7 percent at 36 weeks with orforglipron compared to placebo.¹⁷ The magnitude is somewhat lower than injectable options at similar timepoints, but the convenience of a daily pill versus a weekly injection changes the practical calculus for many patients.

Orforglipron is in Phase 3 development. Eli Lilly has reported positive topline Phase 3 results, and an FDA submission is anticipated.

For lifters, an oral GLP-1 changes the access equation but does not change the lean-mass protection equation. The same protein floor, training signal, and monitoring guardrails apply.

Amycretin

Amycretin is a dual amylin and GLP-1 receptor agonist developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that contributes to satiety signaling and gastric emptying. The dual mechanism targets appetite through two complementary pathways.

Early phase data

In early-phase results, amycretin produced a mean weight loss of approximately 13 percent at 12 weeks, which is a striking rate given the short duration.¹⁸ If that trajectory holds through longer treatment periods, amycretin could produce weight-loss magnitudes that exceed current options.

Amycretin is in early clinical development. No Phase 3 data is available, and FDA approval is likely several years away.

CagriSema

CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide, also developed by Novo Nordisk. The rationale is similar to amycretin: combining amylin-pathway and GLP-1-pathway appetite suppression in a single product.

Phase 3 status

The REDEFINE Phase 3 program has reported results showing CagriSema produced greater weight loss than semaglutide alone.¹⁹ The combination approach suggests that the ceiling for pharmacological weight loss has not yet been reached.

Pipeline summary

Every compound in this table will eventually face the same question that semaglutide and tirzepatide face today: what happens to lean mass when weight drops this fast? The answer will be the same. Protein intake, resistance training, and rate-of-loss monitoring determine whether the weight you lose is mostly fat or an expensive mix of fat and muscle. The drug changes. The protection protocol does not.

The Recomposition Stack Decision Framework

Decision tree

The purpose of a decision tree is to route you to the correct category and the correct set of questions based on your actual situation, rather than letting marketing or peer pressure push you toward a category that does not fit.

Before any peptide conversation

Before you spend any time evaluating which peptide category might apply to you, confirm that the three conditions from the recomposition floor are in place: daily protein at or above 1.6 g/kg of complete protein across three to four feedings, resistance training at least three times per week with compound movements, and a monitored rate of loss via 14-day weight trend. If any of those conditions is missing, the most productive next step is setting the floor in Fuel rather than evaluating compounds.

What Fuel tracks and why it matters

Timeline audit

The Timeline audit in Fuel is built around the principle that rate of loss matters as much as total loss. When you review your Timeline, you can see whether your 14-day weight trend is dropping at a pace your training can survive or whether it is running too fast. The Timeline audit is the first place to look when you suspect that appetite suppression is outrunning your protein strategy.

Meal-level protein tracking

Protein targets during GLP-1 use are tracked per meal and per day, which matters because on these drugs, the daily total can look adequate while individual meals fall well below the leucine threshold. If your tracker shows 170 grams of protein but two of your four meals had less than 20 grams each, the daily number is misleading. Fuel's meal-level tracking catches that pattern.

Setting targets

To set your recomposition targets in Fuel, use the goals flow to establish your protein floor, your rate-of-loss target, and your training frequency. Then use weekly review to audit compliance against those targets each week. The weekly review is where you catch the drift that accumulates over days and turns into lost lean mass over months.

Apple Health integration

If your Apple Health data is incomplete, fix Apple Health permissions before you start interpreting calorie burn, recovery trends, or activity data. Bad input produces bad insights, and the most common reason for misleading health data in Fuel is a permissions gap that prevents the app from reading the full picture.

Health Grade

The Health Grade in Fuel reflects the combined quality of your nutrition, training compliance, and body-composition trajectory during a cut. When the Health Grade drops during a cutting phase, it is usually catching one of the failure modes described in this article: protein falling below the floor, training frequency declining, or rate of loss exceeding what the body can sustain without lean-mass erosion.

Evidence tier summary table

Practical Protocols by Scenario

Man on semaglutide or tirzepatide who wants to preserve muscle

This is the most common scenario in the recomposition audience, and it has the clearest evidence-based protocol. Apply the recomposition floor protocol: protein at 1.6+ g/kg across three to four feedings, resistance training three to four times per week, and rate-of-loss monitoring via the 14-day trend. The specifics for each checkpoint are in the recomposition floor table.

Low-appetite days

On days when GLP-1 appetite suppression makes full meals difficult, use liquid protein sources like whey shakes, Greek yogurt, or casein mixed into a drink to maintain the floor without requiring large meal volumes.

Training quality

Keep the intensity high and trim volume before trimming load. Replacing a hard lower-body session with more steps is a body-composition downgrade for anyone who cares about lean mass. If sessions feel flat for two consecutive weeks, assume under-fueling before assuming you need a different program.

Physician communication

Discuss the following with your prescribing physician: your training goals, your protein strategy, your rate-of-loss targets, and whether the current titration dose is appropriate for your situation. A physician who understands that you are trying to preserve muscle can make better dosing and monitoring decisions than one who only tracks the scale.

Collagen as adjunct

If you are experiencing joint or tendon discomfort during training, adding 15 grams of hydrolyzed collagen plus Vitamin C before targeted loading sessions is reasonable and low-risk. It does not replace any part of the protein or training protocol.

Research peptides add no de-risked value to this scenario. If your protein is adequate, your training is progressive, and your rate of loss is monitored, there is no evidence gap that BPC-157, TB-500, or any other research compound fills. The temptation usually comes from impatience with the rate of progress or discomfort from training during the cut. The first is solved by patience and consistency with the existing protocol, because the evidence-supported rate of loss during a lean-mass-preserving cut is inherently slower than the rate these drugs can produce when unchecked. The second is solved by load management, the collagen protocol, and a sports medicine evaluation if the problem persists.

Weekly checklist

1. Monday: weigh yourself and check the 14-day trend in Timeline.
2. Training days: confirm that you are hitting the protein target at your pre-training and post-training meals.
3. End of each week: use weekly review to audit protein compliance, rate of loss, and training frequency.
4. Flag any metric that has drifted for two consecutive weeks and adjust before the drift compounds.

Man with visceral fat accumulation considering GH-axis options

If you are a man with documented visceral fat accumulation and you are interested in whether growth hormone-axis therapy could be part of your care, the legitimate pathway begins with a physician evaluation.

Tesamorelin is the only FDA-approved GH secretagogue with real trial data showing visceral fat reduction, and its approved indication is HIV-associated lipodystrophy. If you have that condition, tesamorelin is a straightforward clinical conversation with your infectious disease or endocrinology specialist. If you do not have HIV-associated lipodystrophy but have visceral fat accumulation that you believe warrants pharmacological intervention, the pathway is a referral to an endocrinologist or obesity medicine specialist who can evaluate whether off-label tesamorelin use is clinically appropriate for your specific situation.

Legitimate clinic vs. peptide mill

A legitimate clinic takes a thorough medical history, performs a physical examination, orders appropriate lab work including IGF-1 and fasting glucose at minimum, explains the approved indication and the off-label nature of the use, discusses the risks including IGF-1 elevation and glucose-tolerance changes, establishes a monitoring schedule, and does not simultaneously market BPC-157, CJC-1295, and collagen peptides as part of the same "optimization protocol." A peptide mill does the intake in five minutes, mentions none of the risks, and ships the compound.

While on tesamorelin or any GH-axis therapy, use Fuel to track the same metrics that matter for any recomposition phase: protein intake, training compliance, 14-day weight trend, and anchor-lift performance.

The timeline for evaluating tesamorelin results is longer than many men expect. The clinical trials measured visceral adipose tissue changes over 26 weeks. The patience required for a legitimate GH-axis intervention is fundamentally different from the immediacy promised by direct-to-consumer peptide culture.

If tesamorelin is not appropriate for your situation, the redirect is usually toward the GLP-1 pathway for general fat loss, combined with the resistance training and protein infrastructure that supports recomposition.

Athlete post-injury seeing BPC-157 recommended online

You got hurt. Your event is in twelve weeks. Someone in a forum, a podcast comment section, or your gym told you that BPC-157 heals tendons fast and that "everyone uses it." Here is the honest evidence summary.

BPC-157 shows interesting tissue-repair effects in rodent models. There are no published large randomized controlled trials demonstrating that it produces clinically meaningful healing acceleration in humans. USADA classifies it as prohibited under WADA Section S0 (Unapproved Substances) and states that there is not enough human study to establish a safe dose or safe use pattern.

If you are subject to anti-doping testing in any federation, using BPC-157 is a doping violation. It does not matter that you bought it from a clinic. It does not matter that you used it out of competition. S0 substances are prohibited at all times.

The legitimate alternative pathway

The legitimate alternative pathway for injury recovery starts with a sports medicine physician who can evaluate the specific tissue, order imaging if warranted, and design a rehabilitation protocol. Follow the evidence-based rehabilitation pathway outlined in the Research Peptides section: symptom assessment, imaging if indicated, load-modified training, targeted physical therapy, collagen plus Vitamin C protocol, and reassessment at four to six weeks.

The psychology of injury recovery

The psychology of injury recovery deserves acknowledgment because it drives more bad peptide decisions than any other factor. When you are injured and your event is approaching, the emotional weight of the situation makes any intervention that promises speed feel more credible than it is. The better framework is to separate what you can control from what you cannot. You can control your nutrition during recovery, your sleep, your training load around the injury, and whether you get a professional evaluation. What you cannot control is the biological timeline of tissue repair.

If the injury is serious enough to threaten your competition timeline, it is serious enough to warrant a sports medicine evaluation. If the injury would not warrant a doctor visit, it would not warrant injecting a research compound either.

Man using collagen powder who wants to know if it counts toward protein

The direct answer is no. Collagen does not count toward the leucine-threshold protein floor that drives muscle protein synthesis.

Collagen is deficient in the branched-chain amino acids, particularly leucine, that trigger the mTOR signaling pathway responsible for initiating muscle protein synthesis. A serving of 20 grams of collagen protein provides roughly 0 to 0.5 grams of leucine, compared to approximately 2.5 grams of leucine in 20 grams of whey protein. The leucine threshold for stimulating muscle protein synthesis in most adults is approximately 2 to 3 grams per meal. Collagen cannot reach that threshold on its own.

To log collagen without skewing your weekly averages in Fuel, enter it as a supplement or track it separately from your complete protein sources. Your daily protein target should be built around sources that can actually hit the leucine threshold: whey, casein, eggs, dairy, meat, fish, soy, or well-combined plant proteins. Collagen goes on top of that target, not inside it.

When collagen is an adjunct: you are using 15 grams plus Vitamin C before targeted loading for tendon or joint support, you are tracking it separately from your muscle-protein floor, and you understand that it is a connective-tissue strategy.

When collagen is just marketing: you are counting it toward your daily protein target, using a collagen-based protein powder as your primary protein source, or believing that "peptides in your shake" are doing the same job as a therapeutic drug. If any of those describe your situation, adjust your tracking and your expectations.

Monitoring and Biomarker Protocol

The difference between a productive recomposition phase and a destructive one is often invisible for the first four to eight weeks. By the time the consequences show up in the mirror or on the barbell, tissue has already been lost. A structured monitoring protocol catches the drift early, when the correction is small, rather than late, when the damage is expensive to reverse.

This section covers what to measure, how often, and what each metric tells you. The specifics vary by which peptide category you are in, but the principle is the same: measure what matters, at a frequency that catches problems before they compound.

Body-composition monitoring

DEXA scan

Dual-energy X-ray absorptiometry is the most practical clinical method for tracking changes in fat mass, lean mass, and bone mineral density during a recomposition phase. Schedule a baseline scan before starting any peptide therapy or structured cut, then repeat every 12 to 16 weeks. More frequent scans add cost without adding actionable resolution, because body-composition changes at the tissue level need time to accumulate before DEXA can detect them reliably.

What to look for on a DEXA report: total body fat percentage, appendicular lean mass (arms and legs, which is the closest proxy for skeletal muscle), trunk fat (which includes visceral fat), and the ratio of lean-mass change to total weight change. If your lean-mass loss is exceeding 25 to 30 percent of total weight loss, the protein floor or training signal needs attention.

Waist circumference

A simple, free, and surprisingly informative metric. Measure at the iliac crest (top of the hip bone), first thing in the morning before eating or drinking. Track weekly and review the 14-day trend, the same way you track scale weight. Waist circumference responds to visceral fat changes and can move independently of scale weight during a recomposition phase. A man whose scale weight is stable but whose waist circumference is dropping is likely gaining muscle and losing fat simultaneously.

Progress photos

Standardize the conditions: same lighting, same time of day, same poses, same distance from the camera. Take photos every four weeks. Photos are the only monitoring tool that captures the visual changes that body composition numbers can miss, particularly changes in muscle definition and fat distribution that do not show up on a scale.

Training performance markers

Anchor lifts

Pick two to four compound movements that you perform consistently (squat, bench press, deadlift, overhead press, weighted pull-up). Track the top working set weight and RPE each session. Plot these weekly. Two consecutive weeks of declining performance at the same RPE is the earliest reliable signal that under-fueling or under-recovery is eroding muscle quality. This signal typically appears before DEXA changes, before mirror changes, and before scale changes become alarming.

Training volume

Track total weekly sets per major muscle group. During a caloric deficit, expect a modest volume reduction (10 to 20 percent) compared to maintenance or surplus phases. This is normal and does not indicate a problem as long as intensity (load relative to capacity) stays stable. A sharp, unplanned volume drop, where you are cutting sets because you cannot complete them, signals a recovery problem that needs investigation.

Blood markers by peptide category

Different peptide categories create different monitoring needs. The following recommendations are starting points for discussion with your physician, not replacements for clinical judgment.

GLP-1 therapy users:

Tesamorelin or GH-axis therapy users:

General recomposition (no peptide therapy):

How Fuel connects to monitoring

Timeline tracks the 14-day weight trend and flags rate-of-loss deviations. This is the first thing to check each week.

Meal log captures per-meal and per-day protein totals. On GLP-1 therapy, the daily number can look fine while individual meals fall below the leucine threshold. Fuel's per-meal view catches that pattern.

Weekly review aggregates protein compliance, training frequency, and rate of loss into a single audit. When any metric drifts for two consecutive weeks, the weekly review is where you catch it.

Health Grade reflects the combined quality of your nutrition, training, and body-composition trajectory. A dropping Health Grade during a cut is usually catching one of the failure modes described in this article before you notice it yourself.

Related Articles

This article is the hub page for the Peptides for Body Recomposition content cluster. The articles, glossary entries, and help pages linked below provide the detailed execution guidance and background knowledge that this hub article references.

GLP-1 and recomposition cluster

These articles cover the practical side of using GLP-1 medications for body recomposition while protecting lean mass.

Protein Targets and Training Strategy on Semaglutide or Retatrutide is the detailed execution guide for setting protein floors, structuring meals, and maintaining training quality during GLP-1 therapy. If this hub article tells you what lane you are in, that article tells you how to drive.

How to Preserve Muscle on GLP-1 Medications covers the full evidence base and practical protocol for preventing lean-mass loss during medication-assisted weight loss. Read this if your primary concern is the muscle side of the recomposition equation.

How to Stop GLP-1s Without Rapid Fat Regain addresses the off-ramp, which is one of the most neglected parts of the GLP-1 conversation. Build your exit plan while appetite is still controlled, not after the last dose when hunger returns.

The GLP-1 diet guide provides the nutritional foundation for anyone on these medications, with meal architecture, food-tolerance guidance, and side-effect management.

Future cluster pieces in this lane will cover long-term maintenance strategy after GLP-1 discontinuation, body-composition monitoring protocols during medication-assisted cuts, and the intersection of GLP-1 therapy with endurance event training.

Growth hormone secretagogue cluster

The growth hormone secretagogue lane is narrower than most peptide content implies, and the cluster reflects that reality.

Testosterone is linked here because GH-axis discussions in clinic settings frequently overlap with testosterone evaluation, and understanding the distinction between GH optimization and testosterone replacement helps prevent conflation of two separate clinical conversations.

Future cluster pieces in this lane will cover the clinical evaluation pathway for GH-axis concerns, a detailed breakdown of the tesamorelin evidence base, and the distinction between legitimate endocrinology referral and direct-to-consumer anti-aging marketing.

Research peptides cluster

Best Peptide Advice from Huberman, Drive, FoundMyFitness, Tim Ferriss surveys how prominent health and performance podcasters have discussed the peptide landscape, including which compounds they have endorsed, which they have cautioned against, and how their framing has evolved as the evidence picture has developed.

Future cluster pieces in this lane will cover BPC-157 evidence in detail, the supply-chain and quality-control landscape for research peptides, and the USADA and WADA frameworks for understanding why specific compounds are classified as prohibited.

Collagen and connective tissue cluster

Collagen is the glossary entry that covers the biochemistry, supplement forms, and protein-tracking implications of collagen peptides. If the collagen sections of this hub left you with questions about how to log collagen or what distinguishes hydrolyzed collagen from gelatin, the glossary entry provides the detailed reference.

Future cluster pieces in this lane will cover the Baar collagen-loading protocol in detail, rehab nutrition for tendon and ligament injuries, and practical collagen supplementation for event-training blocks.

Emerging compounds cluster

The emerging compounds section of this article will be updated as Phase 3 data matures for survodutide, orforglipron, amycretin, and CagriSema. Individual deep-dive articles for compounds that reach FDA approval will be added to this cluster.

Glossary cross-links

The following glossary entries provide background definitions and detailed context for terms used throughout this article.

• GLP-1 covers the native hormone and its role in appetite and glucose regulation.
• GLP-1 receptor agonist explains the drug class that includes semaglutide and tirzepatide.
• Semaglutide covers the molecule, its approved indications, and the trial program that supports it.
• Tirzepatide covers the dual agonist mechanism and the SURMOUNT trial program.
• Retatrutide covers the triple agonist mechanism and the current state of the clinical development program.
• Collagen covers collagen biochemistry, supplement forms, and protein-tracking implications.
• Testosterone provides context for the hormonal landscape that intersects with GH-axis discussions.

Frequently Asked Questions

Are peptides legal?

The word "peptides" covers too many categories for a single answer. FDA-approved GLP-1 receptor agonists like semaglutide and tirzepatide are legal when prescribed by a licensed physician. Tesamorelin is legal when prescribed for its approved indication. Research peptides like BPC-157 and TB-500 are sold in a grey area where the vendor labels them "for research use only" while marketing them for human use. The FDA has warned consumers about this pattern. Retatrutide is not FDA-approved and cannot be lawfully compounded per federal regulations. Legal to purchase does not mean safe to use, approved for human administration, or free from sport-eligibility consequences.

Is semaglutide a peptide?

Yes. Semaglutide is a peptide molecule that is a modified analog of the human GLP-1 hormone. Calling semaglutide "a peptide" in the same breath as BPC-157 or collagen obscures the fact that semaglutide is an FDA-approved pharmaceutical with extensive clinical trial data, while the others occupy completely different evidence and regulatory categories.

What peptides are banned in sport?

Under the 2026 WADA Prohibited List, growth hormone secretagogues including tesamorelin, sermorelin, CJC-1295, and ipamorelin are prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times. Research peptides including BPC-157 and TB-500 are prohibited under Section S0 (Unapproved Substances). GLP-1 receptor agonists like semaglutide and tirzepatide are not currently prohibited. Collagen peptides are not prohibited. Athletes should verify current status with USADA or their relevant anti-doping authority before any use.

Does BPC-157 work for humans?

The honest answer is that we do not know with confidence. BPC-157 shows tissue-repair effects in rodent models that are genuinely interesting. There are no published large randomized controlled trials demonstrating that it produces clinically meaningful benefits in humans at any dose. The gap between animal data and proven human efficacy is the central problem. USADA has stated that there is not enough human study to establish a safe dose or safe use pattern.

Is tesamorelin the same as sermorelin?

No. They are different compounds with different regulatory histories. Tesamorelin is an FDA-approved growth hormone-releasing factor analog indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Sermorelin is a growth hormone-releasing hormone analog whose original FDA-approved products were withdrawn from the market. Current sermorelin is available through compounding pharmacies but does not carry an active FDA approval. They are not interchangeable, and the evidence base behind each is very different.

Can I use collagen as a protein source?

Collagen provides amino acids but is not a complete protein source for muscle-retention purposes. It is deficient in leucine and the essential amino acids that drive muscle protein synthesis. You should not count collagen toward your leucine-driven protein floor. Track it separately as a supplement and build your protein meals around complete sources like whey, eggs, dairy, meat, fish, or soy.

What peptides are FDA-approved?

In the categories relevant to body recomposition, the FDA-approved compounds are semaglutide (Wegovy for weight management, Ozempic for type 2 diabetes), tirzepatide (Zepbound for weight management, Mounjaro for type 2 diabetes), and tesamorelin (EGRIFTA for HIV-associated lipodystrophy). Retatrutide, CJC-1295, ipamorelin, BPC-157, and TB-500 are not FDA-approved. Sermorelin's original approval was withdrawn.

What does USADA say about peptides?

USADA has issued specific advisories on several peptide categories. The BPC-157 advisory states that the compound is prohibited, not approved for human clinical use, and lacks sufficient human study for safe-dose determination. USADA's annual advisory on the WADA Prohibited List covers growth hormone secretagogues under Section S2. Athletes are directed to check the USADA and WADA resources for the most current substance classification before using any compound.

Are GLP-1s prohibited in competition?

As of the 2026 WADA Prohibited List, GLP-1 receptor agonists including semaglutide and tirzepatide are not prohibited in or out of competition. This status could change in future list updates. Athletes should verify current status with their anti-doping authority before competition. The fact that GLP-1s are not prohibited does not mean their use in weight-class sports or aesthetic competitions is free from ethical scrutiny.

What is a growth hormone secretagogue?

A growth hormone secretagogue is a compound that stimulates the pituitary gland to release growth hormone rather than providing exogenous growth hormone directly. This category includes tesamorelin, sermorelin, CJC-1295, ipamorelin, and various other GHRH and GHRP analogs. The distinction from exogenous GH injection matters because the mechanism, regulatory status, and safety profile differ. Not all growth hormone secretagogues are FDA-approved, and the category spans a wide range from legitimate pharmaceuticals to grey-market research compounds.

Does tirzepatide cause muscle loss?

Tirzepatide causes weight loss, and a fraction of that weight loss comes from lean mass. This is consistent with all forms of weight loss, including diet alone, bariatric surgery, and other medications. The SURMOUNT trials showed substantial total weight reduction, and any time total weight drops by 15 to 20 percent, lean-mass loss is a real concern. The proportion of lean-mass loss relative to total weight loss appears to be in the range typical for this class of drugs. The practical response is to apply the recomposition floor protocol. Greater total weight loss means greater absolute lean-mass exposure, which means the protection protocol is more important.

What should I ask my doctor about peptides?

Start by specifying which category you mean. If you are interested in GLP-1 therapy for weight management, ask whether you qualify based on BMI and comorbidity criteria, what the titration schedule looks like, what protein and training monitoring your physician recommends, and what the off-ramp plan is. If you are interested in tesamorelin, ask about the approved indication, whether your clinical picture supports off-label consideration, and what monitoring IGF-1 and glucose-tolerance changes require. If someone has recommended BPC-157 or another research peptide, ask your physician whether there is human trial evidence supporting its use and what evidence-based alternatives exist for your specific situation. A good physician will not be offended by specific questions. A good physician will be concerned if you are injecting compounds without asking them first.

Is it safe to buy peptides online?

The safety of buying peptides online depends entirely on which peptide and from which source. FDA-approved medications like semaglutide or tirzepatide obtained through a licensed pharmacy with a valid prescription carry the safety assurances of the FDA approval and manufacturing oversight process. Research peptides purchased from websites that sell them with "not for human consumption" labels carry no such assurances. There is no mandatory purity testing, no GMP manufacturing, no batch consistency, and no adverse event reporting. Independent analyses have found contamination, incorrect concentrations, and degradation products in research peptides purchased online. The FDA has explicitly warned consumers about this pattern.

How do I know if a peptide clinic is legitimate?

A legitimate clinic performs a thorough medical evaluation before prescribing anything, explains the approved indication and the off-label nature of any use, orders appropriate baseline labs and establishes a monitoring schedule, discusses risks and contraindications openly, differentiates between evidence tiers rather than marketing all compounds with the same enthusiasm, and does not pressure you to add compounds you did not ask about. Red flags include a minimal intake process, no lab work, marketing that treats all peptide categories as equivalent, bundled "optimization protocols" that combine approved drugs with research compounds, and discouragement of involving your primary care physician.

What are survodutide and orforglipron?

Survodutide is a dual glucagon and GLP-1 receptor agonist in Phase 3 development by Boehringer Ingelheim. Orforglipron is an oral nonpeptide GLP-1 receptor agonist in Phase 3 development by Eli Lilly. Neither is FDA-approved. Both showed meaningful weight loss in Phase 2 trials (approximately 18.7 percent and 14.7 percent respectively). Orforglipron is notable because it would be the first effective oral GLP-1 for obesity. See the emerging compounds section for full details on both compounds and the broader pipeline.

How often should I get a DEXA scan during a cut?

A baseline scan before starting a structured cut or peptide therapy, followed by repeat scans every 12 to 16 weeks, provides the most useful resolution. More frequent scanning adds cost without adding actionable information, because body-composition changes need time to accumulate before DEXA can detect them reliably. See the monitoring section for the full protocol including waist circumference, anchor lifts, and blood markers.

Can I use the recomposition floor protocol without any peptides?

Yes, and it is the recommended starting point. The recomposition floor protocol (protein at 1.6+ g/kg, resistance training three to four times per week, rate-of-loss monitoring) is the foundation for any body recomposition phase, whether or not a peptide or medication is involved. Most men who have not optimized protein intake, training consistency, and sleep have substantial room for body-composition improvement before any compound enters the conversation. Start with the floor. Evaluate compounds only after the fundamentals are producing results and you have a specific reason to believe pharmacological support would add value.

What to read next

If hunger and appetite management are the bottleneck in your cut, start with the GLP-1 diet guide for the nutritional foundation and then read how to preserve muscle on GLP-1 medications for the full lean-mass protection protocol.

If you are already on semaglutide or tirzepatide and want the specific protein and training numbers, go directly to protein targets and training strategy on semaglutide or retatrutide.

If you want to understand how the leading health and performance podcasters have discussed the peptide landscape, including where they agree and where they diverge, read best peptide advice from Huberman, Drive, FoundMyFitness, Tim Ferriss.

If any term in this article was unfamiliar, the GLP-1 glossary entry is a good starting point for the hormonal and pharmacological vocabulary.

Then open Fuel, set your protein floor, audit the week in Timeline, and use weekly review to catch under-fueling before it turns into quiet muscle loss. The peptide decision matters. The system you build around it matters more.